Drugs / Coenzyme A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04839055 | Mar → Apr 2021 | castration-resistant prostate carcinoma | Jiangnan University | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01928342 | Mar 2012 → Sep 2013 | hyperlipoproteinemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01878227 | Jul 2010 → May 2011 | hyperlipoproteinemia | Zhejiang University | Completed | No outcome recorded |
| Phase 3 | NCT01811082 | Jul 2010 → May 2011 | hyperlipoproteinemia | Zhejiang University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01645046 Comparator | Oct 2008 → Jun 2009 | hyperlipoproteinemia | Zhejiang University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Coenzyme A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01811082 ↗ |
| Known as | CoA | “Coenzyme A (CoA) is a ubiquitous essential cofactor that plays a central role in the metabolism of carboxylic acids, including short- and long-chain fatty acids, as well as...” NCT01811082 ↗3“Coenzyme A (CoA) functions as an acyl group carrier and assists in transferring fatty acids from the cytoplasm to mitochondria.” NCT01878227 ↗ “a new hypolipidemic agent, coenzyme A (CoA) to stable statin therapy” PMID 24382338 ↗ Jan 2014 “Coenzyme A (CoA)” NCT04839055 ↗ |
| Known as | Coash | ChEMBL registry synonym — accepted as the source's own label CHEMBL1213327 ↗ |
| Modality | Small molecule | — CHEMBL1213327 ↗ |
| Route | Oral | “high dose CoA orally” NCT01645046 ↗ |